Research Analysts Offer Predictions for MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($2.80) per share for the year, up from their previous forecast of ($3.07). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.99) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($0.13) EPS, FY2029 earnings at $5.13 EPS and FY2030 earnings at $7.93 EPS.

Several other analysts have also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Morgan Stanley reissued an “overweight” rating and issued a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Finally, BTIG Research restated a “buy” rating on shares of Monopar Therapeutics in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.75.

Read Our Latest Stock Report on Monopar Therapeutics

Monopar Therapeutics Stock Performance

MNPR stock opened at $72.00 on Monday. The company’s 50 day moving average price is $82.59 and its 200 day moving average price is $77.41. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82. The firm has a market capitalization of $483.26 million, a price-to-earnings ratio of -29.88 and a beta of 1.62.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.72).

Insiders Place Their Bets

In other news, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $68.35, for a total transaction of $214,755.70. Following the completion of the transaction, the director directly owned 5,373 shares of the company’s stock, valued at approximately $367,244.55. This represents a 36.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director directly owned 5,173 shares of the company’s stock, valued at approximately $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,920 shares of company stock valued at $4,527,913 over the last quarter. Corporate insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Meeder Asset Management Inc. boosted its holdings in Monopar Therapeutics by 18.9% in the third quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock valued at $132,000 after purchasing an additional 262 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Monopar Therapeutics in the first quarter valued at approximately $250,000. Sei Investments Co. raised its holdings in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares in the last quarter. Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Monopar Therapeutics during the first quarter worth approximately $3,458,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Monopar Therapeutics

Investors following MNPR have been watching these stories:

  • Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, implying substantial upside from the cited $72 share price. Cantor Fitzgerald rating article
  • Positive Sentiment: Monopar reported third-quarter 2026 EPS of a $0.72 loss, better than analysts’ consensus estimate of a $0.82 loss. The company also released quarterly results and business updates. Third-quarter results and business updates
  • Neutral Sentiment: HC Wainwright maintained its “Buy” rating and issued 2027 quarterly EPS estimates ranging from a $0.91 to a $1.19 loss per share. The projections indicate continued expected losses, but no change in rating was reported.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Featured Articles

Earnings History and Estimates for Monopar Therapeutics (NASDAQ:MNPR)

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.